These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 31514488)

  • 1. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
    Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
    Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
    Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
    Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
    Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
    Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
    J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
    Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
    BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
    Jindal V; Arora E; Masab M; Gupta S
    Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
    Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
    Front Oncol; 2019; 9():330. PubMed ID: 31114758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.
    Wu ST; Williams CD; Grover PA; Moore LJ; Mukherjee P
    PLoS One; 2018; 13(2):e0193260. PubMed ID: 29462213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
    Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
    Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
    Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
    Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of an
    Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
    Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
    Schmiechen ZC; Stromnes IM
    Front Immunol; 2020; 11():613815. PubMed ID: 33584701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
    Stromnes IM; Schmitt TM; Hulbert A; Brockenbrough JS; Nguyen H; Cuevas C; Dotson AM; Tan X; Hotes JL; Greenberg PD; Hingorani SR
    Cancer Cell; 2015 Nov; 28(5):638-652. PubMed ID: 26525103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.